Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subodh Verma

Showing results (561-570 of 616) with videos related to

Pageof 62
Sort By:
Journal of the American College of Cardiology|November 22, 2023
Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection FractionJaved Butler, Steen Z Abildstrøm, Barry A Borlaug, et al.
The Canadian Journal of Cardiology|August 12, 2022
2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in AdultsG B John Mancini, Eileen O'Meara, Shelley Zieroth, et al.
Cardiovascular Diabetology|July 31, 2025
Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trialMohammad Abdel Jawad, Remo H M Furtado, Russell Esterline, et al.
European Journal of Heart Failure|December 28, 2020
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HFPooja Dewan, Kieran F Docherty, Olof Bengtsson, et al.
The Lancet. Diabetes & Endocrinology|February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
Journal of the American College of Cardiology|November 20, 2024
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart FailureMikhail N Kosiborod, David Z I Cherney, Akshay S Desai, et al.
European Journal of Heart Failure|June 26, 2024
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fractionMingming Yang, Toru Kondo, Pardeep S Jhund, et al.
European Journal of Heart Failure|April 29, 2025
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HFToru Kondo, Pardeep S Jhund, Alasdair D Henderson, et al.
European Heart Journal|May 7, 2025
Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statementStefano Romeo, Antonio Vidal-Puig, Mansoor Husain, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|June 3, 2024
Association between overweight and obesity with coronary artery bypass graft failure: an individual patient data analysis of clinical trialsKevin R An, Sigrid Sandner, Björn Redfors, et al.
Pageof 62

Showing results (561-570 of 616) with videos related to

Sort By:
Pageof 62
Journal of the American College of Cardiology|November 22, 2023
Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection FractionJaved Butler, Steen Z Abildstrøm, Barry A Borlaug, et al.
The Canadian Journal of Cardiology|August 12, 2022
2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in AdultsG B John Mancini, Eileen O'Meara, Shelley Zieroth, et al.
Cardiovascular Diabetology|July 31, 2025
Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trialMohammad Abdel Jawad, Remo H M Furtado, Russell Esterline, et al.
European Journal of Heart Failure|December 28, 2020
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HFPooja Dewan, Kieran F Docherty, Olof Bengtsson, et al.
The Lancet. Diabetes & Endocrinology|February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
Journal of the American College of Cardiology|November 20, 2024
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart FailureMikhail N Kosiborod, David Z I Cherney, Akshay S Desai, et al.
European Journal of Heart Failure|June 26, 2024
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fractionMingming Yang, Toru Kondo, Pardeep S Jhund, et al.
European Journal of Heart Failure|April 29, 2025
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HFToru Kondo, Pardeep S Jhund, Alasdair D Henderson, et al.
European Heart Journal|May 7, 2025
Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statementStefano Romeo, Antonio Vidal-Puig, Mansoor Husain, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|June 3, 2024
Association between overweight and obesity with coronary artery bypass graft failure: an individual patient data analysis of clinical trialsKevin R An, Sigrid Sandner, Björn Redfors, et al.
Pageof 62